Vyjuvek 5,000,000,000 PFU/ML Topical Suspension

RxCUI: 2637767
RxNorm name: Vyjuvek 5,000,000,000 PFU/ML Topical Suspension
Display name: Vyjuvek 5,000,000,000 PFU/ML Topical Suspension
Full name: Vyjuvek 5,000,000,000 PFU/ML Topical Suspension
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:39:29

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
125774	VYJUVEK	beremagene geperpavec-svdt	351(a)	Rx	2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
VYJUVEK	VYJUVEK	Krystal Biotech, Inc.	fe207c8c-04b4-4fdf-87cf-6dbc7eb6e9c2	2025-09-29	Warnings, Adverse reactions	Exact identifier rxcui: 2637767

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
fe207c8c-04b4-4fdf-87cf-6dbc7eb6e9c2	Vyjuvek 5,000,000,000 PFU/ML Topical Suspension [PSN] · beremagene geperpavec-svdt 5000000000 UNT/ML Topical Suspension [Vyjuvek] [SBD] · Vyjuvek 5,000,000,000 PFU/ML Topical Suspension [SY] · Vyjuvek 5,000,000,000 UNT/ML Topical Suspension [SY]	4	6	These highlights do not include all the information needed to use VYJUVEK safely and effectively. See full prescribing information for VYJUVEK. VYJUVEK® (beremagene geperpavec-svdt) biological suspension mixedwith excipient gel for topical applicationInitial U.S. Approval: 2023	20250929